TP53 and breast carcinoma: An extensive study by Anh et al. (2013) in 15,598 BC patients noted that positive p53 expression in hormonal receptor (HR)+/Her2-negative patients is significantly associated with the patient’s response to hormonal therapy and, therefore, could affect overall survival (OS) and breast cancer-specific survival (BCSS) [16].